State Street Corp Purchases 45,529 Shares of MediWound Ltd. (NASDAQ:MDWD)

State Street Corp raised its position in shares of MediWound Ltd. (NASDAQ:MDWD) by 219.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 66,258 shares of the biopharmaceutical company’s stock after buying an additional 45,529 shares during the quarter. State Street Corp’s holdings in MediWound were worth $1,197,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of MDWD. MetLife Investment Management LLC bought a new position in shares of MediWound in the 3rd quarter worth about $89,000. Rhumbline Advisers purchased a new stake in MediWound in the second quarter worth about $131,000. Point72 Asset Management L.P. bought a new position in shares of MediWound during the third quarter valued at approximately $212,000. Bank of New York Mellon Corp purchased a new position in shares of MediWound during the second quarter valued at approximately $342,000. Finally, ARK Investment Management LLC purchased a new position in shares of MediWound during the third quarter valued at approximately $1,806,000. Institutional investors own 46.83% of the company’s stock.

MediWound Price Performance

Shares of MediWound stock opened at $18.00 on Friday. MediWound Ltd. has a 1 year low of $10.95 and a 1 year high of $24.00. The firm’s 50-day moving average is $17.36 and its 200 day moving average is $17.51. The stock has a market cap of $194.15 million, a price-to-earnings ratio of -6.21 and a beta of 0.81.

MediWound (NASDAQ:MDWD) last issued its earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. On average, equities analysts expect that MediWound Ltd. will post -2.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright cut their price target on MediWound from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, November 27th.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.